Abbott Laboratories last reported quarterly results on Oct 21, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $13.0 billion (+14.5% year over year) and diluted EPS of $0.53. It usually reports 16–22 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 21, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 22, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 16–22 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 21, 2026
21 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
13,013
+14.5%
|
920
-44.0%
|
0.53
-43.6%
|
|
Jul 16, 2026
16 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
12,593
+13.0%
|
928
-47.8%
|
0.53
-47.5%
|
|
Apr 16, 2026
16 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
11,164
+7.8%
|
1,077
-18.7%
|
0.61
-19.7%
|
|
Jan 22, 2026
22 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
11,459
+4.4%
|
1,776
-80.8%
|
1.03
-80.4%
|
|
Oct 15, 2025
15 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
11,369
+6.9%
|
1,644
-0.1%
|
0.94
+0.0%
|
|
Jul 17, 2025
17 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
11,142
+7.4%
|
1,779
+36.6%
|
1.01
+36.5%
|
|
Apr 16, 2025
16 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
10,358
+4.0%
|
1,325
+8.2%
|
0.76
+8.6%
|
|
Jan 22, 2025
22 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
10,974
+7.2%
|
9,229
+479.0%
|
5.28
+480.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- IL
- Headquarters
- Abbott Park, IL
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1800
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.